Casein Or Caseinate Patents (Class 530/360)
-
Patent number: 7091320Abstract: The present invention is related to a product derived from milk, substantially free of beta casein from non-human mammals. The invention is also related to the use of such a product especially in relation to diet, more particularly for early infancy, in the prevention of insulin-dependent diabets.Type: GrantFiled: March 4, 2004Date of Patent: August 15, 2006Assignee: Midia LimitedInventor: Paolo Pozzilli
-
Patent number: 6849593Abstract: Pepetides having bifidogenic properties are obtainable by the process of adding proteases to cow'milk or human milk, followed by incubation, centrifugation, acidification, purification by reverse phase HPLC and cation-exchange HPLC, culturing Bifidobacterium bifidum and E. coli in the presence of collected bifidogenic fractions, and isolation of the peptides having bifidogenic properties, and the isolated peptides can be amidated, acetylated, sulfated, phosphorylated, glycosylated, oxidized, or fragmented and still maintain their bifidogenic properties, and combination peptides having bifidogenic properties are obtainable by chemically bonding the peptides having bifidogenic properties, the amidated, acetylated, sulfated, phosphorylated, glycosylated, oxidized, or fragmented peptides having bifidogenic properties, or combinations thereof.Type: GrantFiled: September 16, 1998Date of Patent: February 1, 2005Assignee: Pharis Biotec GmbHInventors: Wolf-Georg Forssmann, Hans-Dieter Zucht, Cornelia Liepke
-
Patent number: 6838431Abstract: The invention relates to a nutritional intervention composition in powder form that is taken before a meal and that extends post meal satiety. The compositions of the invention are comprised of at least one protein, C12-18 fatty acids, preferably oleic acid, all of which stimulate CCK release in the body, and a source of proteinase inhibitor which acts to prevent the deactivation of CCK. The subject compositions preferably additionally contain a source of calcium and are advantageous in that they utilize a source of proteinase inhibitor as opposed to the more costly extracts. The source of proteinase inhibitor is advantageously an extract of potato, soy, or beans containing about 10 weight percent of proteinase inhibitor. The powder compositions are mixed with a suitable liquid, preferably water, prior to ingestion.Type: GrantFiled: February 28, 2002Date of Patent: January 4, 2005Inventor: Robert Portman
-
Patent number: 6824783Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.Type: GrantFiled: June 7, 1995Date of Patent: November 30, 2004Assignee: Duke UniversityInventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild
-
Patent number: 6797810Abstract: A method for modification and isolation of a protein is provided. The method includes the steps of providing a protein selected from the group consisting of whey and soy proteins; providing a reagent that forms sulfite ions; mixing the protein with the reagent under a condition to sulfonate the protein without using an oxidizing agent and to obtain a mixture containing a sulfonated protein; precipitating the sulfonated protein out of the mixture at an acid pH to form a precipitated sulfonated protein and a soluble sulfonated protein; and recovering the precipitated sulfonated protein or soluble sulfonated protein.Type: GrantFiled: January 3, 2001Date of Patent: September 28, 2004Inventor: Jouko Savolainen
-
Patent number: 6780844Abstract: Phosphopeptides containing the Ser(P) cluster sequence motif Ser(P)-Ser(P)-Ser(P)-Glu-Glu- can stabilize their own weight in amorphous calcium phosphate (ACP) and amorphous calcium fluoride phosphate (ACFP). The amorphous phases stabilized by the phosphopeptides are an excellent delivery vehicle to co-localise calcium, fluoride, and phosphate ions at the tooth surface in a slow-release amorphous form producing superior anticaries efficacy. These amorphous phases stabilized by the phosphopeptides also have utility as dietary supplements to increase calcium bioavailability and to help prevent diseases associated with calcium deficiencies.Type: GrantFiled: December 6, 1999Date of Patent: August 24, 2004Assignee: The University of MelbourneInventor: Eric C. Reynolds
-
Publication number: 20040138423Abstract: A series of potent and highly specific insecticidal toxins characterized by an amino acid sequences SEQ ID NO: 2-35.Type: ApplicationFiled: September 5, 2003Publication date: July 15, 2004Inventors: Glenn F. King, Brianna L. Sollod
-
Patent number: 6750203Abstract: The present invention is related to a product derived from milk, substantially free of beta casein from non-human mammals. The invention is also related to the use of such a product especially in relation to diet, more particularly for early infancy, in the prevention of insulin-dependent diabets.Type: GrantFiled: June 11, 1998Date of Patent: June 15, 2004Assignee: Midia LimitedInventor: Paolo Pozzilli
-
Patent number: 6656690Abstract: The present invention provides methods for the determination of the structure of biomolecular targets, as well as the site and nature of the interaction between ligands and biomolecular targets. The present invention also provides methods for the determination of the relative affinity of a ligand for the biomolecular target it interacts with. Also provided are methods for screening ligand or combinatorial libraries of compounds against one or more than one biological target molecules. The methods of the invention also allow determination of the relative binding affinity of combinatorial and other compounds for a biomolecular target. The present invention further provides methods for the use of mass modifying tags for screening multiple biomolecular targets. In a preferred embodiment, ligands which have great specificity and affinity for molecular interaction sites on biomolecules, especially RNA can be identified.Type: GrantFiled: June 19, 2001Date of Patent: December 2, 2003Assignee: ISIS Pharmaceuticals, Inc.Inventors: Stanley T. Crooke, Richard Griffey, Steven Hofstadler
-
Patent number: 6624144Abstract: The present invention relates to novel matrix metalloproteinase (MMP) inhibitors and down-regulators, to a process for the preparation of these inhibitors, to pharmaceutical compositions comprising these inhibitors/down-regulators, to the use of the novel MMP inhibitors for the manufacture of pharmaceutical and research preparations, to a method for inhibiting and down-regulating MMP-dependent conditions either in vivo or in vitro, to a method for inhibiting formation, synthesis, expression activations, and/or functions as well as actions of matrix metalloproteinases, and to the use of the novel MMP inhibitors and down-regulators in biochemical isolation and purification procedures of matrix metalloproteinases.Type: GrantFiled: November 20, 2000Date of Patent: September 23, 2003Assignee: CTT Cancer Targeting Technologies OyInventors: Erkki Koivunen, Timo Sorsa, Tuula Salo
-
Publication number: 20030166510Abstract: Skin remodeling is stimulated at the site of blemished skin using an ionic metal-peptide complex to diminish or remove the skin imperfection. The blemish can be a scar, especially surgical or wound scars, acne scars, keloid scars, and the like, or a skin tag, callus, benign skin mole, stretch marks, facial keratosis, thickened sunspots of the skin, or a vitiligo spot. The peptide-ionic metal complex is comprised of an ionic metal selected from copper(II), tin(II), tin(IV), and zinc(II), and salts thereof, and the peptide component can be a hydrolysis of casein, collagen, elastin, meat products, silk protein, or soybean protein, or a chemically synthesized dipeptide, tripeptide, tetrapeptide or the like which complexes with the ionic metal.Type: ApplicationFiled: October 11, 2001Publication date: September 4, 2003Inventor: Loren R. Pickart
-
Patent number: 6599874Abstract: Antibacterial protein complexes designated as Anti-adhesive Lactalbumin Like Protein (ALLP) are obtained by ion-exchange chromatography of casein and alpha-lactalbumin. Casein isolated from human milk by acid precipitation is subjected to ion-exchange chromatography using an NaCl gradient to obtain six fractions. Fraction six contains the antibacterial protein complex and is recovered. Ion-exchange chromatography of human or bovine alpha-lactalbumin using an NaCl gradient resulted in a fraction that was retained and eluted that contained an antibacterial multimeric protein complex. The protein complexes inhibit attachment of S. pneumoniae and H. influenzae to human respiratory tract epithelial cells when tested in vitro, and the protein complexes can be used to treat a bacterial infection in the respiratory tract. The protein complexes are administered in a pharmaceutical composition or in a food or feed-stuff.Type: GrantFiled: August 17, 2000Date of Patent: July 29, 2003Inventors: Catharina Svanborg, H. Sabharwal
-
Publication number: 20030138905Abstract: Isolated polynucleotides encoding polypeptides expressed in bovine mammary gland tissue are provided, together with genetic constructs and host cells comprising such isolated polynucleotides. Methods for the use of such polynucleotides and polypeptides are also provided.Type: ApplicationFiled: October 2, 2002Publication date: July 24, 2003Applicant: GENESIS RESEARCH AND DEVELOPMENT CORP. LTD.Inventors: Ilkka J. Havukkala, Matthew Glenn, Murray R. Grigor, Adrian J. Molenaar
-
Patent number: 6579849Abstract: A peptide having the amino acid sequence H2N—X1—R—X3—X2—COOH (formula I) wherein X1 is either zero or X1 and/or X2 are a residue representing at least five amino acid residues (symbolized in the one letter amino acid code), preferably naturally occurring amino acids, with the proviso that X1 and/or X2 contain at least one basic amino acid residue immediately followed by a hydrophobic amino acid residue and X1 and/or X2 contain at least one glutamine residue.Type: GrantFiled: September 24, 1998Date of Patent: June 17, 2003Assignee: HaemoPep Pharma GmbHInventors: Wolf-Georg Forssmann, Hans-Dieter Zucht, Manfred Raida, Knut Adermann, Hans-Jürgen Mägert
-
Publication number: 20030096741Abstract: Recombinant beta-casein (&bgr;-CN) proteins and peptides which include the mineral-binding target sequence Xaa-SerP-SerP-Glu-Glu, where SerP is phosphoserine, in which Xaa is any amino acid other than serine or phosphoserine. These phosphopeptides are complexed with minerals, such as calcium, and used as dietary supplements.Type: ApplicationFiled: June 19, 2001Publication date: May 22, 2003Inventors: Charles W. Slattery, John Leonora
-
Patent number: 6558717Abstract: A method for isolating casein and calcium phosphate as separate products from a milk source, comprising the steps of: a) contacting the milk source with carbon dioxide under pressure in order to precipitate the casein; b) separating the casein from the milk source while maintaining the pressure to obtain a casein fraction and a whey fraction; and c) releasing the pressure from the whey fraction to allow calcium phosphate to precipitate therefrom.Type: GrantFiled: December 4, 2000Date of Patent: May 6, 2003Assignee: Campina B.V.Inventors: Clemens Johannes Willibrordus Köllmann, Gerard Willem Hofland, Lucas Antonius Maria Van Der Wielen, Geert-Jan Witkamp
-
Patent number: 6555659Abstract: The present invention is related to a method for the purification of glycomacropeptide (GMP) with an amino acid composition containing no greater that 0.5% (w/w) phenylalanine, comprising the steps of contacting a GMP-containing feedstock with a first anion exchanger under conditions to adsorb the GMP, eluting the adsorbed GMP from the anion exchanger and removing impurities from the GMP-containing eluate by either: (i) contacting the GMP-containing eluate with a cation exchanger in conditions under which the impurities in the eluate are adsorbed onto the cation exchanger, or (ii) precipitating the impurities in GMP-containing eluate using conditions in which the GMP remains i solution, or (iii) contacting the GMP-containing eluate with a second anion exchanger in conditions under which the impurities in the eluate are adsorbed onto the anion exchanger, and recovering the GMP from whichever one or more of the steps (i), (ii) or (iii) was used.Type: GrantFiled: July 24, 2000Date of Patent: April 29, 2003Inventors: John Stephen Ayers, Kay Patricia Coolbear, David Francis Elgar, Mark Pritchard
-
Patent number: 6537760Abstract: In a competitive receptor binding assay for detecting TSH-receptor auto-antibodies in a biological sample, the sample is reacted in a reaction mixture which contains (i) a TSH-receptor or TSH-receptor preparation; (ii) a primary competitor, for example labelled TSH; and (iii) an agent for separating a complex composed of the TSH-receptor and the elements bound thereto of the reaction mixture from the liquid phase. According to the invention, the reaction is carried out in the presence of at least one monoclonal or polyclonal antibody specific against a partial peptide sequence of the TSH eceptor. This specific antibody is used to immobilize a complex of TSH-receptor and primary competitor and/or as secondary competitor for another part of the TSH-receptor auto-antibodies expected in a sample. The primary or secondary competitors are or can be selectively labelled.Type: GrantFiled: August 4, 1999Date of Patent: March 25, 2003Assignee: B.R.A.H.M.S. AktiengesellschaftInventors: Andreas Bergmann, Joachim Struck
-
Patent number: 6521591Abstract: A pharmaceutical composition suitable for enhancing muscular anabolism contains, per daily dose, at least 5 mg of anabolic initiators comprising anabolic growth factors, at least 0.12 g of protein equivalents of anabolic substrates and at least 3 g of anabolic facilitators comprising at least 1 g of creatine or its functional analog. The anabolic initiators may be derived from a non-denatured animal protein, non-denatured being defined as having an F0 of less than 3.0.Type: GrantFiled: February 10, 2000Date of Patent: February 18, 2003Assignee: N.V. NutriciaInventors: Rudolf Leonardus Lodewijk Smeets, Robert Johan Joseph Hageman
-
Patent number: 6506732Abstract: The present invention relates to a mixture of soluble hydrophobic peptides of an enzymatic hydrolysate of milk having skin hydrating properties and percutaneous absorption levels of 4 to 5%. The mixture also exhibits wound healing properties but does not have the allergenicity of the milk-protein. One fraction of the mixture is capable of increasing in vitro the growth rate of cell-cultured keratinocytes by at least 50%. The soluble peptides of the fraction have a molecular weight of about 900 daltons ranging from 200 to 1400 daltons, and an average hydrophobicity of 11 Kcal/mole. The soluble peptides are constituted of 66% hydrophobic amino acids and 17% aromatic amino acids, and have aromatic amino acids and other hydrophobic amino acids located at the C- and N-terminal ending in proportion over 85%. Another fraction is capable of increasing the growth rate of cell-cultured fibroblasts by 37% and the production of collagen by 73%.Type: GrantFiled: January 27, 2000Date of Patent: January 14, 2003Assignee: Universite LavalInventor: Jean Amiot
-
Patent number: 6495344Abstract: A DNA molecule coding for a food protein, such as ovalbumin or casein, modified so that the codons for phenylalanine have been omitted or replaced by codons for one or more other metabolisable amino acids. Also a modified edible protein coded for by such a DNA molecule. Such modified proteins are useful in the nutrition of patients suffering from phenylketonuria.Type: GrantFiled: January 16, 1996Date of Patent: December 17, 2002Assignee: Pharming Holding N. V.Inventors: Noel Gordon Carr, Nicholas Harold Mann
-
Patent number: 6462181Abstract: Improved process for preparing a kappa-caseino glycomacropeptide which comprises adjusting the pH of a solution of a milk starting material to below 4, cold ultrafiltration and concentration of the starting material on a spiral filter. This process is usable in industrial scale without fouling problems and without damaging the usable milk material by-product.Type: GrantFiled: July 21, 2000Date of Patent: October 8, 2002Assignee: Arla Foods AmbaInventors: Hans Henrik Holst, Dereck E. W. Chatterton
-
Publication number: 20020082390Abstract: Novel human polynucleotide and polypeptide sequences are disclosed that be used in therapeutic, diagnostic, and pharmacogenomicType: ApplicationFiled: August 28, 2001Publication date: June 27, 2002Inventors: Carl Johan Friddle, Brenda Gerhardt, Yi Hu
-
Patent number: 6355612Abstract: The subject of the invention is the use of a protein material whose rate of digestion has been reduced, for the preparation of an enteral composition which makes it possible to modulate the postprandial plasma amino acid level, said protein material having been previously treated so as to convert the fast-digesting proteins which it contains to slow-digesting proteins, characterized in that the slow-digesting protein material is a material containing microparticulate gelled proteins combined with polysaccharides under conditions of thermodynamic incompatibility.Type: GrantFiled: July 9, 2001Date of Patent: March 12, 2002Assignee: Nestec S.A.Inventors: Olivier Ballevre, Clara L. Garcia-Rodenas, Kristel Reiffers-Magnani, Bernard Beaufrere, Martial Dangin, Francois Couzy
-
Publication number: 20020009790Abstract: A process is described wherein there is added to an acidic environment, which contains protein, a block-wise enzymatically de-esterified pectin, and wherein the pectin is a high ester pectin. Also described is a recombinant pectin methyl esterase.Type: ApplicationFiled: March 16, 2001Publication date: January 24, 2002Inventors: Tove Martel Ida Elsa Christensen, Jette Dina Kreiberg, Hanne Thorsoe, Hans Christian Buchholt, Preben Rasmussen, John Nielsen
-
Patent number: 6270827Abstract: Compositions containing human milk proteins, including the so-called host resistance factors of human milk, prepared by chemically synthesizing the human milk proteins or by genetic engineering techniques for producing recombinant human milk proteins, are useful for supplementing or enhancing the diet of infants, particularly very-low-birth-weight infants. The human milk proteins include the host resistance factors (HRF) found in human milk, such as lactoferrin (LF), lactoperoxidase (LP), lysozyme (LZ), immunoglobulin-A (IgA), alpha-lactalbumin, alpha, beta, kappa-caseins, and others. The compositions may also include components other than the human milk proteins useful for improved infant nutrition. In the utilization of the compositions of this invention, the compositions would be administered to an infant in at least an amount that the infant would receive if fed substantially only fresh human milk.Type: GrantFiled: October 28, 1999Date of Patent: August 7, 2001Inventors: Gerald E. Gaull, by Florence McSherry Gaull
-
Patent number: 6183754Abstract: The invention relates to a process for in vitro diagnosis of an infection by human cytomegaloviruses. The process consists of contacting cells, possibly carrying the infection, with a monoclonal antibody reacting with a polypeptide of molecular weight 68,000, induced by human cytomagalovirus and which possesses a protein-kinase activity. The detection of the reaction is preferably carried out by immunofluorescence.Type: GrantFiled: June 7, 1995Date of Patent: February 6, 2001Assignee: Institut PasteurInventors: Florian Horaud, Susan Michelson, Octavian Barzu, Andre Boue, Clairo Amadei
-
Patent number: 6180761Abstract: A new casein is disclosed isolated from the milk of Korean cattle with a &bgr;-casein A1H genotype. Amino acid sequence analysis of the casein revealed a length of 209 amino acids, where, in comparison to the more conventional &bgr;-casein variant A2, at amino acid position 25, Arg is replaced by Cys, at position 88, Leu is replaced by Ile, at position 117, Gln is replaced by Glu, at position 175, Glu is replaced by Gln, and at position 195, Gln is replaced by Glu. The new casein variant disclosed can be mass produced by the selective breeding of individual bovines to produce large quantities of milk containing the new casein variant. In one example of such breeding, a female calf was born that subsequently produced the inventive casein at a yield of 4.5 kg per day. The new casein gene can be detected DNA hybridization analysis in bovines secreting the new casein.Type: GrantFiled: March 23, 1999Date of Patent: January 30, 2001Inventors: Sang Kee Han, Yoo Cheol Shin
-
Patent number: 6121421Abstract: The invention provides a method for isolating a protein, specifically .beta.-casein, recombinantly produced in cells that have been genetically engineered to produce the protein. The method involves forming a paste, homogenate or lysate of the cells following fermentation to produce the protein, and performing a two-stage extraction procedure to isolate of the protein. By this method, recombinantly produces .beta.-casein can be isolated with less complexity and greater efficiency than in previously known methods for its isolation.Type: GrantFiled: August 21, 1998Date of Patent: September 19, 2000Assignee: Abbott LaboratoriesInventors: Ellen M. Schwartz, Harold M. Staack
-
Patent number: 6107475Abstract: DNA sequences encoding seven novel seven transmembrane receptors and variants thereof are disclosed as well as materials and methods for production of the same by recombinant techniques. Antibody substances specific for each of the seven transmembrane receptors are disclosed as useful for the modulation of the ligand/receptor binding reactions of the receptors.Type: GrantFiled: April 26, 1999Date of Patent: August 22, 2000Assignee: ICOS CorporationInventors: Ronald Godiska, Patrick W. Gray, Vicki Louise Schweickart
-
Patent number: 6080844Abstract: The present invention involves a process of purifying and recovering a recombinant protein from a suspension of cells. The process of the present invention involves extracting a recombinant protein from a concentrated suspension of cells using a water-miscible organic solvent, isolating the recombinant protein from the suspension of cells, concentrating the recombinant protein to remove the water-miscible organic solvent, precipitating the recombinant protein using an acid, washing the recombinant protein with the salt or free form of a suitable organic acid and recovering the recombinant protein.Type: GrantFiled: April 23, 1998Date of Patent: June 27, 2000Assignee: Abbott LaboratoriesInventors: Ronald E. Carney, Joseph Arndt, Julie R. List, Ellen Marie Schwartz
-
Patent number: 6020015Abstract: Compositions containing human milk proteins, including the so-called host resistance factors of human milk, prepared by chemically synthesizing the human milk proteins or by genetic engineering techniques for producing recombinant human milk proteins, are useful for supplementing or enhancing the diet of infants, particularly very-low-birth-weight infants. The human milk proteins include the host resistance factors (HRF) found in human milk, such as lactoferrin (LF), lactoperoxidase (LP), lysozyme (LZ), immunoglobulin-A (IgA), alpha-lactalbumin, alpha, beta, kappa-caseins, and others. The compositions may also include components other than the human milk proteins useful for improved infant nutrition. In the utilization of the compositions of this invention, the compositions would be administered to an infant in at least an amount that the infant would receive if fed substantially only fresh human milk.Type: GrantFiled: September 6, 1991Date of Patent: February 1, 2000Inventor: Gerald E. Gaull
-
Patent number: 5968901Abstract: The present invention relates to a use of casein derived from milks, preferably human milk, and porcine milk, for the preparation of a substrate for the prophylactic and/or therapeutic treatment of infections of the respiratory tract caused by S. pneumoniae and/or H. influenzae, as well as the diagnostic use of such compositions for diagnosing infections caused by said bacteria.Type: GrantFiled: June 20, 1997Date of Patent: October 19, 1999Inventors: Bengt Andersson, Gustaf Aniansson, Ragnar Lindstedt, Catharina Svanborg Eden
-
Patent number: 5952009Abstract: A method of preventing the transmission of or treating herpesvirus, such as herpes simplex virus infection, or Chlamydia trachomatis comprising administering to a patient a composition which comprises: (i) a protein or peptide containing lysines and an N-terminal amino group, wherein at least one of the lysines or the N-terminal amino group of the protein or peptide, such as casein, .beta.-lactoglobulin, powdered milk or whey, is modified by contact with an aromatic acid anhydride compound, such as trimellitic anhydride, trimellitic anhydride chloride or 3-hydroxyphthalic anhydride and/or (ii) a protein or peptide containing arginines, which is modified by an arginine modifying agent containing at least one carboxyl group, such as p-carboxyphenylglyoxal.Type: GrantFiled: August 28, 1996Date of Patent: September 14, 1999Assignee: New York Blood CenterInventors: Alexander Robert Neurath, Asim Kumar Debnath, Shibo Jiang
-
Patent number: 5942254Abstract: The present invention provides a plasmid containing a promoter sequence, a nucleotide sequence encoding an exogenous protein, and a nucleotide sequence encoding an enzyme capable of modifying the exogenous protein. In a specific embodiment of the invention the encoded exogenous protein is human .beta.-casein and the encoded enzyme is a human kinase capable of phosphorylating recombinant .beta.-casein in a bacterial system. Phosphorylated recombinant human .beta.-casein synthesized using the plasmid of the invention is shown to have the same bioactivity as native human .beta.-casein.Type: GrantFiled: November 6, 1995Date of Patent: August 24, 1999Assignee: Abbott LaboratoriesInventors: Pradip Mukerji, Jennifer Marie Thurmond, Lennart Hansson, Jeffrey Harris Baxter, Robert George Hards
-
Patent number: 5843705Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GaINAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.Type: GrantFiled: February 21, 1995Date of Patent: December 1, 1998Assignee: Genzyme Transgenic CorporationInventors: Paul DiTullio, Harry Meade, Edward S. Cole
-
Patent number: 5834427Abstract: The present invention relates to a purified casein phosphopeptide(CPP) having a novel amino acid sequence and a purified casein including same wherein the 25th Arg from N-terminal in a conventional CPP is replaced by Cys, rendering the CPPs to forming a dimer by disulfide bond. In the corresponding DNA sequence, cytosine is replaced by thymine to cause the amino acid replacement from Arginine(Arg) to Cysteine(Cys). The CPP or the casein containing same has an improved ability of solubilizing minerals and absorbing thereof in animals. The CPP or the beta-casein H containing same can be added to foodstuffs, beverages, medication, cosmetics, feed in an effective amount of enhancing a mineral absorption in animals. An oral composition comprising the beta-casein H or the inventive CPP and a pharmaceutically acceptable carrier can reduce or relieve a dentinal hypersensitivity.Type: GrantFiled: March 25, 1996Date of Patent: November 10, 1998Assignee: Sang Kee HanInventors: Sang Kee Han, Yoo Cheol Shin
-
Patent number: 5807702Abstract: The present invention provides a method of producing phophorylated, recombinant human .beta.-casein having 3 to 5 phosphates in a bacterial cell using a single vector containing in tandem both the nucleotide sequence encoding .beta.-casein and a sequence encoding the enzyme CKII .beta..alpha. which is capable of phosphorylating human .beta.-casein.Type: GrantFiled: November 6, 1995Date of Patent: September 15, 1998Assignee: Abbott LaboratoriesInventors: Pradip Mukerji, Jennifer Marie Thurmond, Lennart Hansson, Jeffrey Harris Baxter, Robert George Hards
-
Patent number: 5780439Abstract: A whey protein hydrolysate is described which is free of allergenics while preserving the structures susceptible of exerting anticipatory regulations to maximize the tolerance and protein metabolism, and mixtures thereof with casein and/or soy protein hydrolysates. Whey protein hydrolysates according to the invention have an amino acid composition comprising at least 2% by weight of tryptophan, less than 5% by weight of threonine, less than 2.8% by weight of methionine whereby 40 to 60% by weight of the amino acids are in the form of tetra- to decapeptides.Type: GrantFiled: August 9, 1996Date of Patent: July 14, 1998Assignee: Novartis Nutrition AGInventors: Francois Mendy, Jean-Maurice Kahn, Loic Roger
-
Patent number: 5773577Abstract: Polymers are provided comprising protein polymers comprising blocks of repeating units and sequences comprising amino acids, individually or in defined sequences, capable of enzyme catalyzed covalent bond formation for cross-linking, as exemplified by glutamine and/or lysine reactive for FXIII catalyzed isopeptide formation or non-amino acid polymers having side chains comprising such amino acids or sequences, which may be used for preparation of articles of manufacture, particularly cross-linkable compositions. By appropriate choice of the polymer, resorbable implantable polymers may be used in internal applications for mammals as formed objects or depots.Type: GrantFiled: March 2, 1995Date of Patent: June 30, 1998Assignee: Protein Polymer TechnologiesInventor: Joseph Cappello
-
Patent number: 5719031Abstract: This invention relates to polymers labeled with fluorescent dye to the point that significant fluorescence quenching occurs, such that degradation of the polymer results in fluorescence enhancement. The resulting fluorescence enhancement is useful for measuring the degradation of such polymers, for example as a result of enzymatic hydrolyis of a protein, carbohydrate, nucleic acid, or other natural or synthetic polymer.Type: GrantFiled: August 14, 1996Date of Patent: February 17, 1998Assignee: Molecular Probes, Inc.Inventors: Richard P. Haugland, Mingjie Zhou
-
Patent number: 5712250Abstract: An enteral nutritional product containing either bovine .kappa.-casein or human .kappa.-casein at a concentration greater than that found in human or bovine milk and sufficient to inhibit infection of mammalian cells by human rotavirus.Type: GrantFiled: October 15, 1996Date of Patent: January 27, 1998Assignees: Abbott Laboratories, University of OklahomaInventors: Pradip Mukerji, Pedro Antonio Prieto, Amanda Eun-Yeong Seo, Jeffrey Harris Baxter, Richard Dale Cummings
-
Patent number: 5710044Abstract: The present invention provides a plasmid containing a promoter sequence, a nucleotide sequence encoding an exogenous protein, and a nucleotide sequence encoding an enzyme capable of modifying the exogenous protein. In a specific embodiment of the invention the encoded exogenous protein is human .beta.-casein and the encoded enzyme is a human kinase capable of phosphorylating recombinant .beta.-casein in a bacterial system. Phosphorylated recombinant human .beta.-casein having 3 or more phosphate groups and synthesized using the plasmid of the invention is shown to have the same bioactivity as native human .beta.-casein.Type: GrantFiled: November 6, 1995Date of Patent: January 20, 1998Assignee: Abbott LaboratoriesInventors: Pradip Mukerji, Jennifer Marie Thurmond, Lennart Hansson, Jeffrey Harris Baxter, Robert George Hards
-
Patent number: 5707968Abstract: The attachment of H. influenzae to human cells, such as oropharyngeal cells, may be inhibited by native human .beta.-casein, a recombinant form of human .beta.-casein, and hydrolysates of both. The human .beta.-casein or hydrolysate may be contained in a liquid enteral nutritional product such as an infant formula. The enteral nutritional product may be used, for example, in the prevention and treatment of otitis media in infants. The human .beta.-casein or hydrolysate may also be administered as a throat spray or nasally using drops or a spray.Type: GrantFiled: October 23, 1996Date of Patent: January 13, 1998Assignee: Abbott LaboratoriesInventors: Pradip Mukerji, Amanda Eun-Yeong Seo, Steven Neal Anderson, Linda Ann Harvey
-
Patent number: 5703212Abstract: A preventive for circulatory diseases which can prevent the onset of circulatory diseases, particularly cerebral stroke, without causing adverse effects such as blood-pressure fluctuation. The preventive contains as the active ingredient a low-molecular-weight peptide fraction prepared by the trypsinization of casein followed by partial purification.Type: GrantFiled: October 11, 1996Date of Patent: December 30, 1997Assignee: Kanebo, Ltd.Inventors: Ryuji Sugai, Umeji Murakami, Yukio Yamori
-
Patent number: 5683984Abstract: An enteral composition of protein, glucides, lipids and minerals, which is suitable for tube feeding, employs native micellar casein as the protein. The composition is prepared by obtaining native micellar casein and combining it with the glucides, lipids and minerals. A dispersion of micellar casein may be obtained by microfiltering milk, particularly skim milk, and glucides and minerals are dispersed in the micellar casein retentate obtained, lipids are added to the resulting dispersion and then the mixture is homogenized and sterilized. The microfiltered retentate may be diafiltered for obtaining the dispersion.Type: GrantFiled: January 30, 1995Date of Patent: November 4, 1997Assignee: Nestec S.A.Inventor: Rolf Jost
-
Patent number: 5681586Abstract: A pharmaceutical composition comprising an improved modified protein sol is used for treating and enhancing the healing of arthritis and cutaneous acne. Prior to being modified, a protein is solubilized and neutralized by an alkali solution containing a molar weight percent ratio of 95:5 KOH/NaOH. Neutralization is allowed to continue for about 5 minute, allowing for complete neutralization of the protein. The neutralized protein is then hydrolyzed by enzymatic digestion. The improved modified protein sol may be then mixed with stabilizing and preserving agents, such as polyvinyl pyrrolidone, if desired. Uses for the improved modified protein composition includes treatment of arthritis and cystic acne.Type: GrantFiled: June 3, 1996Date of Patent: October 28, 1997Inventor: Arthur L. Gordon
-
Patent number: 5646250Abstract: DNA sequences encoding novel cadherins, desginated cadherins-4 through -12, are disclosed along with methods and materials for the recombinant production of the same. Antibody substances specific for the novel cadherins and cadherin peptides are disclosed as useful for modulating the natural binding and/or regulatory activities of the cadherins.Type: GrantFiled: November 1, 1994Date of Patent: July 8, 1997Assignee: Doheny Eye InstituteInventor: Shintaro Suzuki
-
Patent number: 5643880Abstract: The attachment of H. influenzae to human cells, such as oropharyngeal cells, may be inhibited by native human .beta.-casein, a recombinant form of human .beta.-casein, and hydrolysates of both. The human .beta.-casein or hydrolysate may be contained in a liquid enteral nutritional product such as an infant formula. The enteral nutritional product may be used, for example, in the prevention and treatment of otitis media in infants. The human .beta.-casein or hydrolysate may also be administered as a throat spray or nasally using drops or a spray.Type: GrantFiled: May 26, 1994Date of Patent: July 1, 1997Assignee: Abbott LaboratoriesInventors: Pradip Mukerji, Amanda Eun-Yeong Seo, Steven Neal Anderson, Linda Ann Harvey
-
Patent number: 5578577Abstract: The present invention relates to improved specific binding assay methods, kits and devices utilizing chromatographically mobile specific binding reagents labelled with colloidal particles. Specific binding reagents labelled with colloidal particles such as gold and selenium may be subjected to rapid chromatographic solvent transport on chromatographic media by means of selected solvents and chromatographic transport facilitating agents. Further, impregnation of solid substrate materials with labile protein materials including colloidal particle and enzyme labelled reagents in the presence of meta-soluble proteins provides for the rapid resolubilization of such materials which have been dried onto such substrate materials.Type: GrantFiled: June 6, 1995Date of Patent: November 26, 1996Assignee: Abbott LaboratoriesInventors: Shanfun Ching, Patricia A. Billings, Julian Gordon